Descriptor English: | Fondaparinux | ||||||
Descriptor Spanish: |
Fondaparinux
| ||||||
Descriptor Portuguese: | Fondaparinux | ||||||
Descriptor French: | Fondaparinux | ||||||
Entry term(s): |
Arixtra Fondaparinux Sodium Quixidar |
||||||
Tree number(s): |
D09.698.629.429 |
||||||
RDF Unique Identifier: | https://id.nlm.nih.gov/mesh/D000077425 | ||||||
Scope note: | Synthetic pentasaccharide that mediates the interaction of HEPARIN with ANTITHROMBINS and inhibits FACTOR Xa; it is used for prevention of VENOUS THROMBOEMBOLISM after surgery. |
||||||
Allowable Qualifiers: |
AA analogs & derivatives AD administration & dosage AE adverse effects AG agonists AI antagonists & inhibitors AN analysis BL blood CF cerebrospinal fluid CH chemistry CL classification CS chemical synthesis EC economics HI history IM immunology IP isolation & purification ME metabolism PD pharmacology PK pharmacokinetics PO poisoning RE radiation effects SD supply & distribution ST standards TO toxicity TU therapeutic use UR urine |
||||||
Pharm Action: |
Factor Xa Inhibitors |
||||||
Registry Number: | J177FOW5JL | ||||||
CAS Type 1 Name: | (2S,3S,4R,5R,6R)-6-((2R,3R,4R,5R,6R)-6-((2R,3S,4S,5R,6R)-2-carboxy-4-hydroxy-6-((2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfoamino)-2-(sulfooxymethyl)oxan-3-yl)oxy-5-sulfooxyoxan-3-yl)oxy-5-(sulfoamino)-4-sulfooxy-2-(sulfooxymethyl)oxan-3-yl)oxy-3-((2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfoamino)-6-(sulfooxymethyl)oxan-2-yl)oxy-4,5-dihydroxyoxane-2-carboxylic acid | ||||||
Public MeSH Note: | 2019; FONDAPARINUX was indexed under POLYSACCHARIDES 2001-2018 |
||||||
History Note: | 2019 (2001) |
||||||
DeCS ID: | 57641 | ||||||
Unique ID: | D000077425 | ||||||
Documents indexed in the Virtual Health Library (VHL): | Click here to access the VHL documents | ||||||
Date Established: | 2019/01/01 | ||||||
Date of Entry: | 2018/07/09 | ||||||
Revision Date: | 2018/07/03 |
Fondaparinux
- Preferred
Fondaparinux Sodium
- Narrower
Quixidar
- Narrower
Arixtra
- Narrower
Concept UI |
M0403648 |
Scope note | Synthetic pentasaccharide that mediates the interaction of HEPARIN with ANTITHROMBINS and inhibits FACTOR Xa; it is used for prevention of VENOUS THROMBOEMBOLISM after surgery. |
Preferred term | Fondaparinux |
Concept UI |
M0407592 |
Preferred term | Fondaparinux Sodium |
Concept UI |
M0446938 |
Preferred term | Quixidar |
Concept UI |
M0407593 |
Preferred term | Arixtra |
We want your feedback on the new DeCS / MeSH website
We invite you to complete a survey that will take no more than 3 minutes.
Go to survey